Therapy Animals and a Review of the Risk for Zoonotic Transmission


Therapy Animals and a Review of the Risk for Zoonotic Transmission Post & News admin May 24, 2023 Newswise — Animal-Assisted interventions (AAI) are implemented in hospitals and rehabilitation centers to produce many advantages for the patients but could expose them to pathogens transmission, a process known as zoonosis. It is therefore important to consider the possible occurrence of pathogens during the AAIs, and to deïŹne the state of the art of AAIs through a careful beneïŹts/challenges analysis.The review, “Human-Animal Interaction in Animal-Assisted Interventions  (AAI)s: Zoonosis Risks, BeneïŹts, and Future Directions—A One Health Approach,” was recently published in the MDPI journal Animals. The discussion points to possible future perspectives according to a One Health approach in light of the health and safety in AAIs.Positive animal welfare, as preventative medicine to avoid incidents or transmission of pathogens, is a relevant aspect with implications for human and animal health and wellbeing. For this reason, the authors propose a synergy among veterinarians, public health professionals, and epidemiologists, who have a key role in preventing zoonotic disease transmission to safeguard the health of humans, animals, and the environment, in accordance with a One Health vision. The efïŹcacy of AAIs is based on interspecies interactions between an animal and the patient.  Such interaction might be impacted by different factors, such as the characters of both the animal and the handler, the selection of the animal species, an appropriate animal educational protocol, the relationship between the handler and the animal, and mutual relationship among the animal, the patients, and the  members of the working team. The review is the result of an international collaboration between researchers affiliated with the Sbarro Health Research Organization (SHRO), under the direction of Antonio Giordano, M.D., Ph.D., and co-author of the paper.“AAIs constitute a tangible representation of the One Health perspective,” says Giovanna Ligouri, lead author of the paper. “And therefore, we need a multidisciplinary, intersectoral approach between the different health professional ïŹgures who, each according to their own skills, work in a specialized team for the prevention and control of zoonoses, the health and welfare of people, the animals involved, and the environment.”“Different international experts in the ïŹeld of AAI must join forces and develop an action plan,” says Giordano, “in order to determine standardized hygiene, health, and behavioral procedures.”“Di“This recommendation should be aimed at establishing health and behavioral certiïŹcations for animals performing AAI services in the health sector,” says co-author Orlando Paciello, Professor, University degli Studi di Napoli Federico II. Previous PostNext Post

Researchers Target Commonly Mutated or Deleted Gene in Gynecological Cancers


Researchers Target Commonly Mutated or Deleted Gene in Gynecological Cancers Post & News admin May 19, 2023 Newswise — A gene regulating the F-Box and WD Repeat Domain Containing 7 (FBXW7) protein is frequently mutated or deleted in various types of human cancer, including gynecological cancers. Such FBXW7 mutations have been associated with poor prognosis due to increased resistance to treatment. Hence, detection of the FBXW7 mutation status may possibly serve as a suitable diagnostic and prognostic biomarker that plays a central role in determining suitable individualized management.Antonio Giordano, M.D., Ph.D., Founder and Director of the Sbarro Health Research Organization (SHRO), has co-authored the review paper in collaboration with 9 co-authors hailing from different countries, as part of the GYNOCARE COST Action (CA18117). GYNOCARE is a European Network for Gynecological Rare Cancer research: From Concept to Cure, which is chaired by Prof Jean Calleja-Agius, M.D., Ph.D., from the Department of Anatomy at the Faculty of Medicine and Surgery at the University of Malta, Malta. The paper by Di Fiore, R et al. is entitled “The Role of FBXW7 in Gynaecologic Malignancies” and has been published in the latest issue of Cells.The FBXW7 protein has been shown to regulate cellular growth and is a well-characterized tumor suppressor. This protein is a crucial component of the Skp1-Cullin1-F-box (SCF) complex, which is a ubiquitin ligase. This complex aids in the degradation of many oncoproteins, such as cyclin E, c-JUN, c-MYC, NOTCH, and MCL1, via the ubiquitin-proteasome system (UPS).Gynecological cancers include ovarian, uterine/endometrial, cervical, vaginal, and vulvar cancers. These malignancies pose a huge worldwide health-socio-economic burden due to their high incidence and mortality among women, irrespective of age. Lack of screening, limited awareness of specific symptoms, late diagnosis, or even misdiagnosis, combined with limited treatment options for advanced gynecological cancers, are the main contributing factors leading to the high morbidity and mortality, thus stressing the need for further advances in the area of gynecological cancers. There is mounting evidence indicating that the aberrant expression of FBXW7 is involved in the development of gynecological cancers. This review provides an update on the role of FBXW7, not only as a potential biomarker, but also as a therapeutic target for novel oncologic treatments, particularly in the management of gynecological cancers. Previous PostNext Post

Antonio Giordano, M.D., Ph.D. Honored with da Vinci Award by the Italian Heritage and Culture Committee of New York


Antonio Giordano, M.D., Ph.D. Honored with da Vinci Award by the Italian Heritage and Culture Committee of New York Post & News admin April 28, 2023 This blog was originally published in NewswiseMembers of the Board of Directors of the Italian Heritage and Culture Committee-NY, Inc. (IHCC-NY) honored Dr. Antonio Giordano, Founder and Director of the Sbarro Health Research Organization (SHRO) on April 24, 2023, with its coveted Leonardo da Vinci award, awarded annually by the 47-year-old cultural organization. A special presentation dinner hailed Giordano for his professionalism and concern for the well-being of humanity, attended by Giordano’s son and colleagues at Il Gattopardo New York City. Consul General Fabrizio DiMichele attended and praised the noted doctor for his “
contributions to the world and humankind.”In presenting the da Vinci award to Dr. Giordano, Comm. Joseph Sciame stated: “We are so honored that you have allowed us to honor you with our special recognition as you join a long line of prior recipients who have each richly deserved our award. This award is special in that for 2022 we hailed the theme of Italian and Italian American Nobel Prize Laureates, and you are certainly one that is most deserving, in that we hope someday to see your name among those great men and women so honored.” Members of the Board gathered with great applause about the good doctor, as there has always been great respect for this very special man of science. Giordano was born in Naples, Italy, and attended the University of Naples ‘Luigi Vanvitelli’, later appointed as professor at Temple University, and is unique in that he has attained both a medical and doctorate degree.  SHRO is a non-profit organization committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes, and other chronic diseases, and most importantly to foster the training of young doctors in a spirit of professionalism and humanism.In accepting the award, Giordano stated: “The role of the IHCC has proven invaluable in preserving the bedrock values of Italian culture, first and foremost family and faith, and in celebrating the many contributions of Italians to world civilization from Art and Architecture to Literature, Music, Medicine and the Sciences. The profound and lasting impact of the Italian diaspora on the countries of immigration is undeniable, including and especially America, where Italian culture is deeply woven into the fabric of modern American life. IHCC awardees exemplify these values and cultural accomplishments which have proven central to the advancement of American society as we know it. In my life, I have striven to promote these values, the values of IHCC, through the exchange of scientific knowledge between Italy and America. Through SHRO we have supported the education and training of some 400 bright young Italian scholars here in the US, many of whom, having acquired advanced skills afforded through American technology innovation in medical science, have returned to Italy to make ground-breaking contributions of their own to the practice of medical science in Italy. I am honored and humbled by this recognition, and I pledge to you that I will continue to devote my life and career to the eradication of cancer in our lifetimes.”The IHCC, now in its 47th year, has selected themes over the years related to important Italian and Italian American personages. In some years, it salutes broad-based issues relative to the Italian American experience. For 2023, the theme selected is “The Joys of Learning Italian” in a positive and proactive effort to enhance the study, learning, and appreciation of the Italian language. Additional information will be forthcoming in preparation for the month of October 2023, when the wider community recognizes Italian Heritage and Culture Month, as declared by civic and elected leaders.Professor Antonio Giordano, M.D., Ph.D. is the Founder and Director of Sbarro Health Research Organization based at the College of Science and Technology, Temple University, Philadelphia. Connect with him on his social media channels to follow more updates: (Facebook, LinkedIn, Twitter, Instagram) Previous PostNext Post

Blood cancers linked to HIV: Insights from recent studies ~ Dr. Antonio Giordano (Sbarro Institute)

Blood cancers linked to HIV: Insights from recent studies ~ Dr. Antonio Giordano (Sbarro Institute) Post & News admin April 6, 2023 This blog was originally published in La Voce Di New York by Prof Antonio Giordano, click here to read in Italian.Recent research demonstrates that anti-retroviral (ARV) therapies to HIV patients prevent almost two-thirds of cancers, including Kaposi’s sarcoma and non-Hodgkin lymphoma, a cancer of the lymph nodes.These neoplastic diseases are frequently linked to patients with advanced AIDS or HIV-positive. This finding is very intriguing but larger studies are required to evaluate the use of these drugs.As the HIV infection predominantly targets CD4 T lymphocytes, white blood cells, as well as macrophage monocytes, the insurgency of tumors is particularly dangerous for AIDS patients. When advanced AIDS and seropositivity affect the function of these cells, patients are more vulnerable than others to tumor-related disorders as in fact white cells “protect” us from tumors and infections.Particularly aggressive tumors that can damage the skin, mouth cavity, digestive system, and lymph nodes include Kaposi’s sarcoma. A type of multicentric vascular tumor (KS) can develop in immunosuppressed people who contract the hhv8 virus. The hhv8 virus is spread by saliva, intercourse, organ transplants, or blood transfusions involving hhv8-positive individuals.Oncology is a specific area of medicine that examines the connections between the HIV virus and the onset of tumors in people with cancer or in people who are positive and have tumors. Because neoplastic pathology in these patients is interconnected with more aggressive infections associated with immunodeficiency, with issues related to anti-retroviral therapy response, with toxicity and pharmacological interactions, it is clear that the oncological pathology in patients with advanced AIDS or seropositivity is more “complex” than that in patients without advanced AIDS.Recent studies have revealed some encouraging news. The diagnosis of tumors in AIDS patients has “significantly” decreased since the introduction of potent anti-retroviral combinatorial therapies in 1996–1997. Nonetheless, their “risk” is still higher than the general population. The use of antiretrovirals has improved the health of individuals with associated neoplastic disorders and turned HIV infection from a lethal to a chronic disease. Achieving a “chronicization” allowing patients to live as long as possible is what we hope to achieve for cancer treatment. To accomplish this as soon as possible, it is important to create oncological prevention and surveillance programs based on the use of immunotherapy and other cutting-edge, personalized medicine, which take into account the regression and interaction of tumors treated with anti-retroviral drugs.Professor Antonio Giordano, M.D., Ph.D. is the Founder and Director of Sbarro Health Research Organization based at the College of Science and Technology, Temple University, Philadelphia. Connect with him on his social media channels to follow more updates: (Facebook, LinkedIn, Twitter, Instagram) Previous PostNext Post

New Review Reveals the Critical Role of Progranulin in Cancer


New Review Reveals the Critical Role of Progranulin in Cancer Post & News admin April 6, 2023 Originally published in Newswise A recent review paper published in the journal Cancers highlights the important role of the growth factor progranulin in the initiation and progression of cancer.  Progranulin has been found to have a pro-tumorigenic role in cancer by promoting cancer cell proliferation, migration, invasiveness, anchorage-independent growth, and resistance to chemotherapy. In addition, progranulin regulates the tumor microenvironment, affects the function of cancer-associated fibroblasts, and modulates tumor immune surveillance. However, the molecular mechanisms of progranulin oncogenic function are not fully understood.This review was recently published by researchers working with the Sbarro Health Research Organization (SHRO) and the Sbarro Institute for Cancer Research and Molecular Medicine, at Temple University, led by Founder and Director Antonio Giordano, M.D. Ph.D.The paper, Progranulin Oncogenic Network in Solid Tumors, was written by Elisa Ventura, Ph.D.,  and Andrea Morrione, Ph.D., Temple University, with co-authors including Dr. Giordano and others at Thomas Jefferson University and universities in Milan and Catania.The authors provide a detailed overview of what is currently known about the function of progranulin in tumors, with a focus on its molecular mechanisms of action and regulation. Understanding the details of progranulin function can potentially bring the identification of novel targets for therapy in cancer.This work covers the current literature supporting the notion that progranulin action is critical in the initiation and progression of mesothelioma. Further study of progranulin could lead to the development of new therapeutic strategies targeting progranulin in mesothelioma and other cancers.”This paper is significant because it highlights the critical role of progranulin in the development of cancer and provides valuable insights into the possibility of progranulin as a novel target for cancer therapy,” says Giordano. With further research, progranulin could potentially be used as a diagnostic and prognostic marker for various cancer types. Previous PostNext Post